Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 2004-07-08

Employees: -

Market Cap: -

Website: http://www.pinganzhengxing.com

Clinical Trials

Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Fulvestrant 500 mg
Drug: Exemestane 25 mg

First Posted Date: 2016-01-06

Last Posted Date: 2017-01-02

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 148

Registration Number: NCT02646735

Locations: 🇨🇳
National Cancer Institute, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer

Phase 3

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Zoledronic acid

First Posted Date: 2015-11-03

Last Posted Date: 2015-11-03

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 430

Registration Number: NCT02595138

Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

Phase 2

Conditions: Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

Interventions: Other: chemotherapy followed by radiotherapy
Other: radiotherapy followed by chemotherapy
Drug: IPGDP regimen chemotherapy

First Posted Date: 2015-09-25

Last Posted Date: 2018-01-03

Lead Sponsor: Chinese Academy of Medical Sciences

Registration Number: NCT02560441

Locations: 🇨🇳
People's Hospital of Guangxi, Nanning, China
🇨🇳
Fourth Hospital of Hebei Medical University, Shijiazhuang, China
🇨🇳
Shanxi Dayi Hospital, Taiyuan, China

and more 2 locations

Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection

Not Applicable

Conditions: Hepatocellular Carcinoma

Interventions: Procedure: TACE
Drug: Sorafenib

First Posted Date: 2015-09-01

Last Posted Date: 2016-03-15

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 90

Registration Number: NCT02537158

Locations: 🇨🇳
Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Bei jing, China

Optimization of Preoperative Treatment in Locally Advanced Rectal Cancer

Phase 3

Recruiting

Conditions: Cancer, Rectum

Interventions: Radiation: Long-term chemoradiotherapy
Radiation: Short-course radiotherapy with neoadjuvant chemotherapy

First Posted Date: 2015-08-26

Last Posted Date: 2021-07-16

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 600

Registration Number: NCT02533271

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, Beijing, China

Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer

Phase 3

Conditions: Gastric Adenocarcinoma

Interventions: Drug: Docetaxel;oxaliplatin;s1
Drug: oxaliplatin;s1

First Posted Date: 2015-07-30

Last Posted Date: 2015-08-10

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 380

Registration Number: NCT02512380

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

Short Course Radiotherapy Combined With Chemotherapy in Stage IV Rectal Cancer With Resectable Liver Metastases

Phase 2

Conditions: Stage IV Rectal Cancer, Liver Metastasis, Resectable

Interventions: Radiation: Short course radiotherapy

First Posted Date: 2015-07-29

Last Posted Date: 2015-07-29

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 47

Registration Number: NCT02510378

Locations: 🇨🇳
Dept of Radiation oncology, Cancer Hospital , Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳
Cancer Hospital, CAMS, Beijing, China

A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Icaritin

First Posted Date: 2015-07-14

Last Posted Date: 2015-07-14

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 28

Registration Number: NCT02496949

Locations: 🇨🇳
Cancer institute & hospital, chinese academy of medical sciences, Beijing, Beijing, China

Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma

Phase 3

Conditions: Esophageal Cancer

Interventions: Radiation: radiation
Drug: paclitaxel; cisplatin

First Posted Date: 2015-06-03

Last Posted Date: 2015-09-01

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 386

Registration Number: NCT02461043

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

Esophagectomy in Middle and Lower Thoracic Esophageal Cancer Patients Through Left Versus Right Transthoracic Approach

Phase 3

Conditions: Esophageal Cancer

Interventions: Procedure: Left thoracotomy
Procedure: Right thoracotomy

First Posted Date: 2015-05-20

Last Posted Date: 2015-05-20

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 800

Registration Number: NCT02448979

Locations: 🇨🇳
Cancer hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy